Biotechnology - Live Biotherapeutics / Dermatology
Strategic Profile
Azitra's pipeline includes ATR-12 for Netherton syndrome in Phase Ib trials, ATR-04 for chemotherapy-induced rash in Phase 1/2, and ATR-01 for ichthyosis vulgaris. The company has a collaboration with Bayer, which provides validation and potential commercialization support for its engineered microbiome approach.
Cyborg Score Rationale
Early-stage biotech with differentiated live biotherapeutic platform and pharma partnership support, but minimal employee base (12 FTE) and pre-revenue stage creates execution and funding risk. Clinical progress and Bayer alignment are positives, but market validation remains uncertain.
Top Insights
Live biotherapeutic products (genetically modified bacteria) represent differentiated approach versus traditional small molecules or biologics in dermatology
Extremely lean operation (12 employees) suggests capital efficiency but limits execution bandwidth and commercial capabilities
Bayer partnership validation indicates institutional confidence in science, though revenue and near-term milestones remain undisclosed
Ultra-small market cap and trading volume suggest low liquidity and high volatility typical of clinical-stage biotech
Named Competitors
Microbiome Therapeutics — Engineered microbiome and bacterial therapies for gastrointestinal and systemic conditions
Precision Dermatology — Traditional small molecule and biologic treatments for skin diseases
Recent Developments
Company traded at $0.31 as of recent data, down 3.16%, indicating market headwinds or macro pressure
Maintains active Phase Ib and Phase 1/2 clinical programs across dermatology franchise
Open the full interactive Azitra, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.